A decision support system based on artificial intelligence and systems biology for the simulation of pancreatic cancer patient status.

Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2163-8306 (Electronic) Linking ISSN: 21638306 NLM ISO Abbreviation: CPT Pharmacometrics Syst Pharmacol Subsets: MEDLINE

Publication: 2015- : Hoboken, NJ : Wiley
Original Publication: New York, NY : Nature Pub. Group

Artificial Intelligence* ; Pancreatic Neoplasms*/genetics; Humans ; Systems Biology ; Computer Simulation

Oncology treatments require continuous individual adjustment based on the measurement of multiple clinical parameters. Prediction tools exploiting the patterns present in the clinical data could be used to assist decision making and ease the burden associated to the interpretation of all these parameters. The goal of this study was to predict the evolution of patients with pancreatic cancer at their next visit using information routinely recorded in health records, providing a decision-support system for clinicians. We selected hematological variables as the visit's clinical outcomes, under the assumption that they can be predictive of the evolution of the patient. Multivariate models based on regression trees were generated to predict next-visit values for each of the clinical outcomes selected, based on the longitudinal clinical data as well as on molecular data sets streaming from in silico simulations of individual patient status at each visit. The models predict, with a mean prediction score (balanced accuracy) of 0.79, the evolution trends of eosinophils, leukocytes, monocytes, and platelets. Time span between visits and neutropenia were among the most common factors contributing to the predicted evolution. The inclusion of molecular variables from the systems-biology in silico simulations provided a molecular background for the observed variations in the selected outcome variables, mostly in relation to the regulation of hematopoiesis. In spite of its limitations, this study serves as a proof of concept for the application of next-visit prediction tools in real-world settings, even when available data sets are small.
(© 2023 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.)

Trends Cancer. 2019 Aug;5(8):467-474. (PMID: 31421904)
Biochem Biophys Res Commun. 2013 Aug 16;438(1):161-8. (PMID: 23876312)
Insights Imaging. 2019 Apr 4;10(1):44. (PMID: 30949865)
Front Immunol. 2017 Jun 19;8:639. (PMID: 28674530)
Neuron. 2015 Apr 22;86(2):360-73. (PMID: 25905810)
PLoS One. 2020 Feb 13;15(2):e0228926. (PMID: 32053711)
Diagnostics (Basel). 2021 Nov 26;11(12):. (PMID: 34943442)
Am J Transl Res. 2020 Oct 15;12(10):6723-6739. (PMID: 33194068)
Curr Opin Hematol. 2021 Nov 1;28(6):417-423. (PMID: 34232142)
Curr Pharmacol Rep. 2018 Apr;4(2):145-156. (PMID: 33520605)
CPT Pharmacometrics Syst Pharmacol. 2023 Jul;12(7):916-928. (PMID: 37002678)
Nat Commun. 2020 Apr 7;11(1):1732. (PMID: 32265505)
Clin J Am Soc Nephrol. 2017 Apr 3;12(4):603-613. (PMID: 28348030)
N Engl J Med. 2013 Oct 31;369(18):1691-703. (PMID: 24131140)
Oncotarget. 2021 Feb 16;12(4):316-332. (PMID: 33659043)
Front Immunol. 2018 Mar 06;9:434. (PMID: 29559975)
PLoS One. 2021 Oct 28;16(10):e0258210. (PMID: 34710093)
Haematologica. 2020 Jan;105(1):59-70. (PMID: 31004027)
Semin Oncol. 2019 Feb;46(1):28-38. (PMID: 30638624)
Drugs. 2018 May;78(7):737-745. (PMID: 29754293)
CA Cancer J Clin. 2018 Jan;68(1):7-30. (PMID: 29313949)
J Clin Med. 2021 Nov 12;10(22):. (PMID: 34830541)
Oncotarget. 2016 Mar 29;7(13):16936-47. (PMID: 26943578)
N Engl J Med. 2011 May 12;364(19):1817-25. (PMID: 21561347)
J Immunother Cancer. 2022 Jan;10(1):. (PMID: 35064009)
Biochem Biophys Res Commun. 2020 Dec 17;533(4):1457-1463. (PMID: 33268026)
Nat Rev Clin Oncol. 2015 Jun;12(6):319-34. (PMID: 25824606)
Transl Res. 2015 Jul;166(1):103-10. (PMID: 25497276)
Front Psychiatry. 2021 Nov 03;12:741170. (PMID: 34803764)
J Clin Oncol. 2020 Aug 5;:JCO2001364. (PMID: 32755482)
Nat Cancer. 2021 Oct;2(10):1102-1112. (PMID: 35121878)
Cell Physiol Biochem. 2008;21(1-3):183-92. (PMID: 18209485)
Oncologist. 2019 Jun;24(6):772-782. (PMID: 30446581)

Date Created: 20230401 Date Completed: 20230717 Latest Revision: 20240522

20250114

PMC10349189

10.1002/psp4.12961

37002678